Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 16/20 | 1.00 |
| ▸ | FNTB | P49356 | 14/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 8/20 | 0.85 |
| ▸ | HRAS | P01112 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8586036 | 1.00 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL8365606 | 1.00 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL6056511 | 1.00 | FNTA (1.00) | FNTAFNTBTDP1PGGT1BHRAS | |
| Hydrochloric Acid SCHEMBL8492799 | 0.99 | FNTA (0.98) | FNTAFNTBTDP1PGGT1BHRAS | |
| Hydrochloric Acid SCHEMBL8492805 | 0.99 | FNTA (0.98) | FNTAFNTBTDP1PGGT1BHRAS | |
| Hydrochloric Acid SCHEMBL29686212 | 0.99 | FNTA (0.98) | FNTAFNTBTDP1PGGT1BHRAS | |
| Trifluoroacetic Acid SCHEMBL5078474 | 0.95 | FNTA (0.90) | FNTAFNTBTDP1PGGT1BHRAS | |
| Trifluoroacetic Acid SCHEMBL29395402 | 0.95 | FNTA (0.90) | FNTAFNTBTDP1PGGT1BHRAS | |
| Trifluoroacetic Acid SCHEMBL5078478 | 0.95 | FNTA (0.90) | FNTAFNTBTDP1PGGT1BHRAS | |
| SCHEMBL16111993 | 0.92 | FNTA (1.00) | FNTAFNTBTDP1PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719410-A1 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4635574-A2 | COMBINATION THERAPY TO TREAT KRAS MUTANT CANCERS | Semmelweis Egyetem (HU) | 2025-10-22 | — | — | EP | claimed |
| EP-4426303-B1 | FARNESYL-TRANSFERASE INHIBITORS AND KRAS INHIBITORS FOR TREATING KRAS MUTANT CANCERS | SEMMELWEIS EGYETEM (HU) | 2025-10-08 | — | — | EP | claimed |
| EP-4604958-A1 | METHOD OF TREATING ADULT-ONSET AUTOSOMAL DOMINANT LEUKODYSTROPHY (ADLD) | Agency for Science, Technology and Research (SG) | 2025-08-27 | — | — | EP | claimed |
| WO-2025101692-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR ANOMALIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2024249551-A1 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | claimed |
| EP-4426303-A1 | FARNESYL-TRANSFERASE INHIBITORS AND KRAS INHIBITORS FOR TREATING KRAS MUTANT CANCERS | Semmelweis Egyetem (HU) | 2024-09-11 | — | — | EP | claimed |
| CN-117940155-A | Immunogenic composition, preparation method and application thereof | 清华大学 | 2024-04-26 | — | — | CN | claimed |
| WO-2024085805-A1 | METHOD OF TREATING ADULT-ONSET AUTOSOMAL DOMINANT LEUKODYSTROPHY (ADLD) | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-04-25 | — | — | WO | claimed |
| US-20240058321-A1 | FARNESYL-TRANSFERASE INHIBITORS AND KRAS INHIBITORS FOR TREATING KRAS MUTANT CANCERS | HUN-REN TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2024-02-22 | — | — | US | claimed |
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | DUKE UNIVERSITY (US) | 2024-02-22 | — | — | US | claimed |
| US-20230248683-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMAS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY INC (US) | 2023-08-10 | — | — | US | claimed |
| WO-2023079320-A1 | FARNESYL-TRANSFERASE INHIBITORS AND KRAS INHIBITORS FOR TREATING KRAS MUTANT CANCERS | SEMMELWEIS EGYETEM (HU) | 2023-05-11 | — | — | WO | claimed |
| WO-2023036249-A1 | IMMUNOGENIC COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 清华大学 | 2023-03-16 | — | — | WO | claimed |
| US-20220401436-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-12-22 | — | — | US | claimed |
| US-20220305001-A1 | METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2022-09-29 | — | — | US | claimed |
| CN-109985242-B | Application of mevalonate metabolic pathway inhibitor and alphavirus in preparation of antitumor drugs | 广州威溶特医药科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20220117927-A1 | METHODS OF TREATING SQUAMOUS CELL CARCINOMAS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220071941-A1 | THERAPIES FOR SQUAMOUS CELL CARCINOMAS | KURA ONCOLOGY, INC. | 2022-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058335-A1 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | ABL2, ABL1, VAV1 | FNTA 31/4885FNTB 41/4885TDP1 2702/4885 |
| US-20220401436-A1 | METHODS FOR THE TREATMENT OF CANCERS THAT HAVE ACQUIRED RESISTANCE TO KINASE INHIBITORS | BRAF, FNTA, FNTB | FNTA 2/4885FNTB 3/4885TDP1 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.